Overview of Albaconazole
Cryptococcus neoformans, Antimicrob Agents Chemother, 2005;48:384–7.
10. Morera Y, Torres Rodriguez JM, Jimenez T, et al., Antifungal susceptibilities of 113 clinical isolates of Cryptococcus neoformans and Candida spp. to the new antifungal albaconazole (UR-9825) respect to voriconazole and fluconazole, Trends Med Mycol, 2003;143–7.
11. Trilles L, Fernández-Torres B, Lazéra Mdos S, et al., In vitro antifungal susceptibility of Cryptococcus gattii, J Clin Microbiol, 2004;42:4815–7.
12. Morera-Lopez, Y, Torres-Rodríguez JM, Jiménez-Cabello T, et al., Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole, Med Mycol, 2005;43:505–10.
13. Serena C, Pastor FJ, Ortoneda M, et al., In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts, Antimicrob Agents Chemother, 2004;48:2724–6.
14. Capilla J, Ortoneda M, Pastor FJ, et al., In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi, Antimicrob Agents Chemother, 2001;45:2635–7.
15. Verweij PE, Nationwide survey of in vitro activity of antifungal agents against clinical Aspergillus fumigatus isolates cultured between 1945 and 1988 in The Netherlands, Presented at: the 38th ICAAC, San Diego, Abstract J–33, 460, 24–27 September 1998.
16. Gené J, Azón-Masoliver A, Guarro J, et al., Cutaneous infection caused by Aspergillus ustus, an emerging opportunistic fungus in immunocompromissed patients, J Clin Microbiol, 2001;39:1134–6.
17. García-Martos P, Guarro J, Gené J, et al., Onychomycosis caused by Aspergillus sclerotiorum, J Mycol Med, 2001;11:222–4.
18. Meletiadis J, Meis JF, de Hoog GS, et al., In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugss, Mycoses, 2000;43:309–12.
19. Meletiadis J, Meis J, Rijs A, et al., In vitro susceptibility of 64 clinical Scedosporium prolificans and Scedosporium apiospermum isolates of antifungal agents, Mycoses, 1999;42:144–5.
20. Meletiadis J, Meis JF, Mouton JW, et al., In vitro activities of new and conventional antifungal agents against clinical
Scedosporium isolates, Antimicrob Agents Chemother, 2002;46:62–8.
21. Carrillo AJ, Guarro J, et al., In vitro activities of four novel triazoles against Scedosporium spp, Antimicrob Agents Chemother, 2001;45:2151–3.
22. Serena C, Ortoneda M, Capilla J, et al, In vitro activities of new antifungal agents against Chaetomium spp and inoculum standardization, Antimicrob Agents Chemother, 2003;47:3161–4.
23. Fernandez-Torres B, Carrillo AJ, Martín E, et al., In vitro activities of 10 antifungal drugs against 508 dermatophyte strains, Antimicrob Agents Chemother, 2001;45:2524–8.
24. Ortoneda M, Capilla J, Javier Pastor F, et al., In vitro interactions of licensed and novel antifungal drugs against Fusarium spp, Diagn Microbiol Infect Dis, 2004;48:69–71.
25. Azor M, Gené J, Cano J, et al., Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex, Antimicrob Agents Chemother, 2007;51:1500–3.
26. Azor M, Gené J, Cano J, et al., In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticilloides (F. moniliforme) and Fusarium thapsinum, Antimicrob Agents Chemother, 2008;52:2228–31.
27. Ortoneda M, Capilla J, Pastor FJ, et al., In vitro interactions of approved and novel drugs against Paecilomyces spp., Antimicrob Agents Chemother, 2004;48:2727–9.
28. Trilles L, Fernández-Torres B, Dos Santos Lazéra M, et al., In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases, Antimicrob Agents Chemother, 2005;49:3952–4.
29. Marimon R, Serena C, Gené J, et al., In vitro antifungal susceptibilities of five species of Sporothrix, Antimicrob Agents Chemother, 2008;52:732–4.
30. Marimon R, Gené J, Cano J, et al., Sporothrix luriei: a rare fungus from clinical origin, Med Mycol, 2008;46:621–5.
31. Gilgado F, Serena C, Cano J, et al., Antifungal susceptibilities of the species of the Pseudallescheria boydii complex, Antimicrob Agents Chemother, 2006;50:4211–3.
32. Urbina J, Lira R, Visbal J, Bartroli, J, In vitro antiproliferative effects and mechanisms of action of the triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, Antimicr Agents Chemother, 2000;44:2498–502.
33. Urbina J, Lira R, Visbal G, et al., Sterol biosynthesis inhibitors for Chagas’ disease, Curr Opin Anti Infect Invest Drugs, 2000;2:40–6.
34. Urbina J, Specific treatment of Chagas’ disease: current status and new developments, Curr Opin Anti Infect Invest Drugs, 2001;14:733–41.
35. González GM, Robledo E, Garza-González E, et al., Efficacy of albaconazole against Candida albicans in vaginitis model, Antimicrob Agents Chemother, 2009;53:4540–1.
36. Algueró M, In vitro and in vivo activity of albaconazole, Presented at: Focus Fungal Infect, Abstract 1194, Maui, 19–21 March 2003.
37. Capilla J, Yustes C, Mayayo E, et al., Efficacy of albaconazole in the treatment of disseminated infection by Scedosporium prolificans in rabbits, Antimicr Agents Chemother, 2003;47:1948–51.
38. Guedes PMM, Urbina JA, de Lana M, et al., Activity of the new triazole derivative albaconazole against Trypanosome (schizotrypanum) cruzi in dog hosts, Antimicr Agents Chemother, 2004;48:4286–92.
39. Conte L, UR-9825, a novel, broad spectrum triazole for the treatment of fungal infections: pharmacokinetic study in animals, Abstract P–91, Presented at: Trends in Invasive Fungal Infections 4, 139, Barcelona, 5–8 November 1997.
40. De la Cruz G, Safety and preliminary pharmacokinetics of an oral solution containing albaconazole after single and multiple dose administration to healthy volunteers, Presented at: Focus on Fungal Infections 13, Abstract 1193, Maui, 19–21 March 2003.
41. Corcoran G, Effect of food on the absorption of albaconazole from 50 mg capsules in healthy volunteers, Presented at: 21st World Congress on Dermatology, Abstract 6729, Buenos Aires, 30 September – 5 Octoberr 2007.
42. Nadal T, In vitro and in vivo human metabolism of albaconazole, Presented at: Focus on Fungal Infections 13, Abstract 1192, 19–21 March 2003, Maui.
43. De la Cruz G, et al. Lack of QTc effects of albaconazole, a new triazole antifungal, Presented at: Focus on Fungal Infections 13, Abstract 1191, Maui, 19–21 March 2003.
44. Internal data. 45. Bartroli J, A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis, Abstract M–722, Presented at: 45th ICAAC, Washington, 16–19 December 2005.
EUROPEAN INFECTIOUS DISEASE
91
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92